The role of immune-related adverse event (irAE) occurrence, as a surrogate predictor of the clinical efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non–small-cell lung-cancer with a programmed death-ligand 1 expression of ≥ 50%. A total of 1010 patients were evaluated, and after a 6-week landmark selection, 877 patients were included. We confirmed the irAE profile of first-line, single-agent pembrolizumab, in a large, real-life cohort of patients with non–small-cell lung-cancer with programmed death-ligand 1 expression of ≥ 50%. The occurrence of irAEs might be considered a surrogate of clinical activity and improved outcomes also in this setting.
- First line
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Cancer Research